NCT00620412View on ClinicalTrials.gov

Probiotics to Enhance Immunogenicity of Influenza Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2009

Conditions
Healthy
Interventions
DIETARY_SUPPLEMENT

Lactobacillus rhamnosus

2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10\^10 LGG organisms.

DIETARY_SUPPLEMENT

placebo control

2 capsules by mouth twice a day for 28 days

BIOLOGICAL

Influenza Virus Vaccine Live, Intranasal

intranasal spray, 0.1ml per nostril, one time dose

All Listed Sponsors
collaborator

Amerifit Brands Inc

INDUSTRY

lead

Tufts Medical Center

OTHER

NCT00620412 - Probiotics to Enhance Immunogenicity of Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter